199 related articles for article (PubMed ID: 34478133)
1. The Therapeutic Antibody Profiler for Computational Developability Assessment.
Raybould MIJ; Deane CM
Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133
[TBL] [Abstract][Full Text] [Related]
2. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
3. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment.
Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ
MAbs; 2022; 14(1):2080628. PubMed ID: 35771588
[TBL] [Abstract][Full Text] [Related]
4. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
[TBL] [Abstract][Full Text] [Related]
5. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
7. Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling.
Raybould MIJ; Turnbull OM; Suter A; Guloglu B; Deane CM
Commun Biol; 2024 Jan; 7(1):62. PubMed ID: 38191620
[TBL] [Abstract][Full Text] [Related]
8. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.
Zhang W; Wang H; Feng N; Li Y; Gu J; Wang Z
Antib Ther; 2023 Jan; 6(1):13-29. PubMed ID: 36683767
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
[TBL] [Abstract][Full Text] [Related]
10. SAbPred: a structure-based antibody prediction server.
Dunbar J; Krawczyk K; Leem J; Marks C; Nowak J; Regep C; Georges G; Kelm S; Popovic B; Deane CM
Nucleic Acids Res; 2016 Jul; 44(W1):W474-8. PubMed ID: 27131379
[TBL] [Abstract][Full Text] [Related]
11. Blueprint for antibody biologics developability.
Mieczkowski C; Zhang X; Lee D; Nguyen K; Lv W; Wang Y; Zhang Y; Way J; Gries JM
MAbs; 2023; 15(1):2185924. PubMed ID: 36880643
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Optimization of Antibody-Based Biotherapeutics for Improved Developability: A Practical Guide for Molecular Modelers.
Thorsteinson N; Comeau SR; Kumar S
Methods Mol Biol; 2023; 2552():219-235. PubMed ID: 36346594
[TBL] [Abstract][Full Text] [Related]
13. DOTAD: A Database of Therapeutic Antibody Developability.
Li W; Lin H; Huang Z; Xie S; Zhou Y; Gong R; Jiang Q; Xiang C; Huang J
Interdiscip Sci; 2024 Mar; ():. PubMed ID: 38530613
[TBL] [Abstract][Full Text] [Related]
14. An accelerated surface-mediated stress assay of antibody instability for developability studies.
Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P
MAbs; 2020; 12(1):1815995. PubMed ID: 32954930
[TBL] [Abstract][Full Text] [Related]
15. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling.
Park E; Izadi S
MAbs; 2024; 16(1):2362788. PubMed ID: 38853585
[No Abstract] [Full Text] [Related]
16. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.
Makowski EK; Wu L; Gupta P; Tessier PM
MAbs; 2021; 13(1):1895540. PubMed ID: 34313532
[TBL] [Abstract][Full Text] [Related]
17. Embedding Dynamics in Intrinsic Physicochemical Profiles of Market-Stage Antibody-Based Biotherapeutics.
Licari G; Martin KP; Crames M; Mozdzierz J; Marlow MS; Karow-Zwick AR; Kumar S; Bauer J
Mol Pharm; 2023 Feb; 20(2):1096-1111. PubMed ID: 36573887
[TBL] [Abstract][Full Text] [Related]
18. Structure, heterogeneity and developability assessment of therapeutic antibodies.
Xu Y; Wang D; Mason B; Rossomando T; Li N; Liu D; Cheung JK; Xu W; Raghava S; Katiyar A; Nowak C; Xiang T; Dong DD; Sun J; Beck A; Liu H
MAbs; 2019; 11(2):239-264. PubMed ID: 30543482
[TBL] [Abstract][Full Text] [Related]
19. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
[TBL] [Abstract][Full Text] [Related]
20. A machine learning strategy for the identification of key
Waight AB; Prihoda D; Shrestha R; Metcalf K; Bailly M; Ancona M; Widatalla T; Rollins Z; Cheng AC; Bitton DA; Fayadat-Dilman L
MAbs; 2023; 15(1):2248671. PubMed ID: 37610144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]